Could HIF-1 alpha be a novel biomarker for the clinical course and treatment of pulmonary embolism?


Kerget B. , Afşin D., Aksakal A., Aksakal A., Aşkin S. , Araz Ö.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.50, no.4, pp.963-968, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.3906/sag-1908-93
  • Title of Journal : TURKISH JOURNAL OF MEDICAL SCIENCES
  • Page Numbers: pp.963-968
  • Keywords: HIF-1 alpha, pulmonary thromboembolism, hypoxia, ENDOTHELIAL GROWTH-FACTOR, VEGF, THROMBOSIS

Abstract

Background/aim: Pulmonary embolism (PE) is associated with high morbidity and mortality rates if not diagnosed and treated rapidly. The aim of our study was to investigate the relationship between levels of hypoxia-induced factor-1 alpha (HIF-1 alpha) and clinical course and prognosis in patients with intermediate low-risk, intermediate high-risk, and high-risk PE.